Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NASDAQ | Common Stock
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.
In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin.
Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures.
It markets its products through a direct sales force and distributors.
The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001.
LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | 0.49 Increased by +48.48% | 0.44 Increased by +11.36% |
| Aug 1, 24 | 0.52 Increased by +44.44% | 0.47 Increased by +10.64% |
| May 2, 24 | 0.44 Increased by +62.96% | 0.39 Increased by +12.82% |
| Feb 27, 24 | 0.38 Increased by +52.00% | 0.36 Increased by +5.56% |
| Nov 1, 23 | 0.33 Increased by +32.00% | 0.30 Increased by +10.00% |
| Aug 1, 23 | 0.36 Increased by +125.00% | 0.32 Increased by +12.50% |
| May 2, 23 | 0.27 Increased by 0.00% | 0.25 Increased by +8.00% |
| Feb 23, 23 | 0.25 Decreased by -10.71% | 0.26 Decreased by -3.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 54.82 M Increased by +15.63% | 11.14 M Increased by +48.51% | Increased by +20.32% Increased by +28.44% |
| Jun 30, 24 | 55.85 M Increased by +11.44% | 11.83 M Increased by +46.04% | Increased by +21.17% Increased by +31.04% |
| Mar 31, 24 | 53.48 M Increased by +13.60% | 9.89 M Increased by +63.69% | Increased by +18.49% Increased by +44.09% |
| Dec 31, 23 | 48.88 M Increased by +19.36% | 8.46 M Increased by +50.44% | Increased by +17.32% Increased by +26.03% |
| Sep 30, 23 | 47.41 M Increased by +21.48% | 7.50 M Increased by +37.50% | Increased by +15.82% Increased by +13.19% |
| Jun 30, 23 | 50.12 M Increased by +19.02% | 8.10 M Increased by +130.38% | Increased by +16.16% Increased by +93.58% |
| Mar 31, 23 | 47.08 M Increased by +18.99% | 6.04 M Increased by +0.03% | Increased by +12.83% Decreased by -15.93% |
| Dec 31, 22 | 40.95 M Increased by +3.67% | 5.63 M Decreased by -8.87% | Increased by +13.74% Decreased by -12.10% |